RecruitingNCT07118306

COPD Exacerbation Follow Up

A Multicenter Study of the Impact of a COPD Identification and Referral System on Patient Follow Up and Outcomes After an Acute COPD Exacerbation Resulting in an Emergency Department Visit or Hospitalization

Sponsor

Viz.ai, Inc.

Enrollment

485 participants

Start Date

Feb 27, 2026

Study Type

OBSERVATIONAL

Conditions

COPD, Chronic Obstructive Pulmonary Disease

Summary

The goal of this study is to evaluate the impact of implementing an AI-enabled clinical workflow tool (Viz COPD) on respiratory specialist follow up and clinical outcomes after an acute exacerbation.

Eligibility

Min Age: 40 Years

Inclusion Criteria5

Patients aged 40 years or older at the time of arrival to the emergency department.
Patients with a clinical diagnosis of COPD who present to the emergency department for a moderate or severe COPD exacerbation.
A moderate exacerbation is defined as an acute exacerbation requiring either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics.
A severe exacerbation is defined as an acute exacerbation requiring hospitalization, or observation for >24 hours in emergency department/urgent care facility or resulting in death.
Patients on dual (LABA/LAMA, LABA/ICS, LAMA/ICS) or triple (LABA/LAMA/ICS) long-acting bronchodilator inhalers.